Sept 6 (Reuters) - Bicara Therapeutics said on Friday it

is seeking a valuation of up to $828 million in its initial

public offering in the United States, as new listings continue

to flock the markets.

The company, backed by global alternative asset management

firm TPG and Indian biopharmaceutical firm Biocon

, is aiming to raise $211.8 million by selling about

11.8 million shares priced between $16 and $18 apiece, it said

in a regulatory filing.

Capital markets have turned the corner in 2024 with the

second half expected to be more stronger than the first. A

possible interest rate cut this month and strong market rally

has increased the number of companies waiting in the pipeline

that are seeking to go public.

Boston-based Bicara is a clinical-stage biopharmaceutical

company that develops therapies to improve outcomes for cancer

patients.

The company plans to list its common stock on Nasdaq under

the symbol "BCAX".

Morgan Stanley and TD Cowen are among the lead underwriters

for the IPO.